Evidence network for deaths_(OS)

1SOLAR-1 (patients with PIK3CA mutant status), 20191CALGB 40302, 20141EGF30008 (HER2-positive), 20091PALOMA-3, 20161PENELOPE-B, 20211KCSG-BR15-10, 20191MONALEESA-2, 20161MONARCH 2, 20202E2112, 2021 ENCORE301, 20131PALOMA-1, 20161MONALEESA-3, 20182BELLE-2 (full population), 2017 BELLE-2 (patients with known PI3K status), 20171NCT02756364 (sapanisertib weekly), 20221NCT02187991 - HR-positive and HER2-negative cohort, 20211QUILT-2.015, 20131Huang, 20201SYSUCC-002, 2022aromatase inhibitorfulvestrantletrozoleendocrine therapyexemestanepaclitaxelexemestane plus ridaforolimuschemotherapycapecitabineplacebotrastuzumab plus chemotherapyabemaciclib plus aromatase inhibitoralpelisib plus fulvestrantlapatinib plus fulvestrantlapatinib plus letrozolepalbociclib plus fulvestrantpalbociclib plus endocrine therapyribociclib plus letrozoleribociclib plus endocrine therapyabemaciclib plus fulvestrantabemaciclib plus endocrine therapyentinostat plus exemestanepalbociclib plus letrozoleribociclib plus fulvestrantipatasertib plus paclitaxelbuparlisib plus fulvestrantsapanisertib plus fulvestrantdalpiciclib plus fulvestranttucidinostat plus exemestanealisertib plus paclitaxelcapivasertib plus paclitaxeldalotuzumab plus ridaforolimus plus exemestanealpelisib plus letrozoleganitumab plus endocrine therapyOBI-822/OBI-821 plus cyclophosphamidemetformincelecoxib plus endocrine therapytrastuzumab plus endocrine therapybuparlisib plus letrozolecediranib plus fulvestrantdirect evidencenetwork meta-analysis
T vs. C aromatase inhibitorfulvestrantletrozoleendocrine therapyexemestanepaclitaxelexemestane plus ridaforolimuschemotherapycapecitabineplacebotrastuzumab plus chemotherapyabemaciclib plus aromatase inhibitoralpelisib plus fulvestrantlapatinib plus fulvestrantlapatinib plus letrozolepalbociclib plus fulvestrantpalbociclib plus endocrine therapyribociclib plus letrozoleribociclib plus endocrine therapyabemaciclib plus fulvestrantabemaciclib plus endocrine therapyentinostat plus exemestanepalbociclib plus letrozoleribociclib plus fulvestrantipatasertib plus paclitaxelbuparlisib plus fulvestrantsapanisertib plus fulvestrantdalpiciclib plus fulvestranttucidinostat plus exemestanealisertib plus paclitaxelcapivasertib plus paclitaxeldalotuzumab plus ridaforolimus plus exemestanealpelisib plus letrozoleganitumab plus endocrine therapyOBI-822/OBI-821 plus cyclophosphamidemetformincelecoxib plus endocrine therapytrastuzumab plus endocrine therapybuparlisib plus letrozolecediranib plus fulvestrant
aromatase inhibitor---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
fulvestrantNA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
letrozoleNANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
endocrine therapyNANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
exemestaneNANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
paclitaxelNANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
exemestane plus ridaforolimusNANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
chemotherapyNANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
capecitabineNANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
placeboNANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
trastuzumab plus chemotherapyNANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
abemaciclib plus aromatase inhibitorNANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANANA
alpelisib plus fulvestrantNANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANANA
lapatinib plus fulvestrantNANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANANA
lapatinib plus letrozoleNANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANANA
palbociclib plus fulvestrantNANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANANA
palbociclib plus endocrine therapyNANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANANA
ribociclib plus letrozoleNANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANANA
ribociclib plus endocrine therapyNANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANANA
abemaciclib plus fulvestrantNANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANANA
abemaciclib plus endocrine therapyNANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANANA
entinostat plus exemestaneNANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANANA
palbociclib plus letrozoleNANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANANA
ribociclib plus fulvestrantNANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANANA
ipatasertib plus paclitaxelNANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANANA
buparlisib plus fulvestrantNANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANANA
sapanisertib plus fulvestrantNANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANANA
dalpiciclib plus fulvestrantNANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANANA
tucidinostat plus exemestaneNANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANANA
alisertib plus paclitaxelNANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANANA
capivasertib plus paclitaxelNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANANA
dalotuzumab plus ridaforolimus plus exemestaneNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANANA
alpelisib plus letrozoleNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANANA
ganitumab plus endocrine therapyNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANANA
OBI-822/OBI-821 plus cyclophosphamideNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANANA
metforminNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANANA
celecoxib plus endocrine therapyNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANANA
trastuzumab plus endocrine therapyNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NANA
buparlisib plus letrozoleNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---NA
cediranib plus fulvestrantNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA---

pathologies: 356,351,357,352,354,353,358,359 - treatments: 1447 result logic